Okada C, Eda R, Miyagawa H, Sugiyama H, Hopp R J, Bewtra A K, Townley R G
Allergic Disease Center, Creighton University School of Medicine, Omaha, NB 68178.
Int Arch Allergy Immunol. 1994;103(4):384-90. doi: 10.1159/000236658.
Cetirizine, a potent H1-antagonist, has been reported to inhibit eosinophil migration into human skin. We, therefore, further evaluated the effect of cetirizine on eosinophil function, including superoxide anion generation, chemotaxis, and eosinophil peroxidase (EP) release. In allergic subjects, superoxide anion generation 60 min after platelet-activating factor (PAF) activation was inhibited by concentrations of cetirizine ranging from 0.01 to 1 microgram/ml (2.612 x 10(-8) to 2.612 x 10(-6) M). No significant inhibition was observed in normal subjects. PAF (10(-6) M)-induced eosinophil chemotaxis was also inhibited by cetirizine. In allergic subjects, percent inhibitions were 47.5 +/- 6.1% at 0.01 microgram/ml, 50.8 +/- 5.1% at 0.1 microgram/ml and 58.9 +/- 6.4% at 1 microgram/ml of cetirizine. In allergic subjects, N-formyl-methionyl-lencyl-phenylalanine induced eosinophil chemotaxis was inhibited by cetirizine, although EP release was not. These results suggest cetirizine has effects on eosinophils which can not be explained by H1-blockade alone.
西替利嗪是一种强效H1拮抗剂，据报道可抑制嗜酸性粒细胞向人体皮肤的迁移。因此，我们进一步评估了西替利嗪对嗜酸性粒细胞功能的影响，包括超氧阴离子生成、趋化作用和嗜酸性粒细胞过氧化物酶（EP）释放。在过敏受试者中，血小板活化因子（PAF）激活60分钟后的超氧阴离子生成受到浓度范围为0.01至1微克/毫升（2.612×10⁻⁸至2.612×10⁻⁶ M）的西替利嗪的抑制。在正常受试者中未观察到明显抑制。PAF（10⁻⁶ M）诱导的嗜酸性粒细胞趋化作用也受到西替利嗪的抑制。在过敏受试者中，西替利嗪浓度为0.01微克/毫升时抑制率为47.5±6.1%，0.1微克/毫升时为50.8±5.1%，1微克/毫升时为58.9±6.4%。在过敏受试者中，西替利嗪抑制了N-甲酰甲硫氨酰-亮氨酰-苯丙氨酸诱导的嗜酸性粒细胞趋化作用，尽管EP释放未受抑制。这些结果表明西替利嗪对嗜酸性粒细胞有作用，而这不能仅用H1阻断来解释。
